Naratriptan-Hormosan

Naratriptan, the active ingredient in Naratriptan-Hormosan, is a Triptan presented as an oral tablet for oral use. It provides acute treatment of migraine attacks in adults and is prescribed when other analgesics are insufficient.

GNH USA supplies Naratriptan-Hormosan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the Triptan class and is used for the acute management of migraine attacks.

- Migraine (with aura): provides rapid relief of headache pain and associated symptoms. - Migraine (without aura): reduces the severity and duration of an acute migraine episode. - Menstrual migraine: offers effective acute treatment for migraine linked to menstrual cycles.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Dizziness: transient light‑headedness or vertigo. - Fatigue: temporary tiredness or reduced energy. - Dry mouth: reduced salivation leading to throat discomfort.

Serious or Rare Side Effects: - Chest pain: may indicate cardiac ischemia and requires immediate evaluation. - Serotonin syndrome: risk when combined with other serotonergic agents, presenting with agitation, hyperthermia, and neuromuscular abnormalities. - Severe hypertension: sudden rise in blood pressure that can be dangerous. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Myocardial infarction: rare but life‑threatening heart attack.

Before prescribing Naratriptan, clinicians should evaluate cardiovascular health and potential drug interactions. - Assess cardiovascular risk: avoid use in patients with uncontrolled hypertension or coronary artery disease. - Avoid use with ergotamine derivatives: combined vasoconstriction may increase vascular complications. - Caution with serotonergic drugs: monitor for signs of serotonin syndrome. - Use carefully in hepatic impairment: dose adjustment may be required. - Store at room temperature: keep in the original pack, protect from moisture.

Naratriptan may interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Ergotamine derivatives: additive vasoconstriction can precipitate severe vascular events. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome. - SSRIs or SNRIs combined with other serotonergic agents: heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - Other triptans: cumulative serotonergic effect may raise adverse event risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase naratriptan plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness.